Comparing Povetacicept and Tacrolimus Treatments for Adults With Primary Membranous Nephropathy Aged 18 to 75 Years

What this Trial Is About

Researchers are studying the effects of povetacicept in adults with primary membranous nephropathy pMN, a kidney condition. This study aims to evaluate how well povetacicept works, its safety, and how well patients tolerate it compared to another treatment called tacrolimus. The trial includes adults aged 18 to 75 years and is conducted by Vertex Pharmaceuticals Incorporated. Participants will be randomly assigned to receive either one of two doses of povetacicept, which is given as a solution for subcutaneous injection, or tacrolimus capsules taken orally. The dosing for povetacicept is based on previous phase 2b results. This study follows a sequential design and is conducted in phases 2 and 3. During the study, researchers will monitor participants for clinical remission of their kidney disease at 104 weeks. They will also track safety by recording adverse events up to week 112. Participants will have scheduled visits to assess their condition and treatment response. The total study duration extends up to nearly four years, concluding in late 2028.

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)